On September 21, BEONE MEDICINES rose 3.01% in regular trading, trading at HKD 219.0 per share, with turnover of HKD 362 million.

The move came amid a broad-based rally across the Hong Kong-listed biotech sector. Notable gainers included Akeso up over 6%, Kelun-Biotech up over 5%, and WuXi Biologics up over 4%, reflecting a sector-wide uplift in sentiment. CITIC Securities noted that Chinese innovative drugs have entered a global value realization phase, with leading internationalized biopharma companies poised to unlock product value on the world stage.

On fundamentals, BEONE MEDICINES reported robust H1 results with revenue of USD 3.219 billion, up 32.3% year-over-year, and net profit of USD 464 million, surging 385.8%. Its flagship product Brukinsa generated USD 2.342 billion in global sales, up 34.5%, accounting for 74% of product revenue. Adjusted net profit reached USD 820 million, more than doubling year-over-year. CLSA recently named the company a top pick within the China biotech space, citing solid fundamentals.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)